Lista de obras -

Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors.

artículo científico publicado en 2017

Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations

artículo científico publicado en 2018

CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation

article

CDK13 cooperates with CDK12 to control global RNA polymerase II processivity

artículo científico publicado en 2020

CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer

artículo científico publicado en 2019

CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.

artículo científico publicado en 2014

CDK7-dependent transcriptional addiction in triple-negative breast cancer.

artículo científico publicado en 2015

Corrigendum: Small genomic insertions form enhancers that misregulate oncogenes

artículo científico publicado en 2017

Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors

artículo científico publicado en 2017

Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors

scientific article published on 29 August 2016

Cut homeobox 1 causes chromosomal instability by promoting bipolar division after cytokinesis failure

artículo científico publicado en 2011

Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8

artículo científico publicado en 2018

Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype

artículo científico publicado en 2019

Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13

scientific article published on 05 June 2020

Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1.

artículo científico publicado en 2011

Discovery of selective aminothiazole aurora kinase inhibitors

artículo científico publicado en 2008

ER stress signaling promotes the survival of cancer 'persister cells' tolerant to EGFR tyrosine kinase inhibitors

artículo científico publicado en 2017

EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma

artículo científico publicado en 2018

Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs

artículo científico publicado en 2013

High MITF Expression is Associated with Super-enhancers and Suppressed by CDK7 Inhibition in Melanoma.

artículo científico publicado en 2018

High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors

artículo científico publicado en 2011

Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML

artículo científico publicado en 2018

Identification of small molecule inhibitors targeting the Zika virus envelope protein

artículo científico publicado en 2019

Leveraging kinase inhibitors to develop small molecule tools for imaging kinases by fluorescence microscopy

artículo científico publicado en 2012

MT FdR: a ferredoxin reductase from M. tuberculosis that couples to MT CYP51

scientific journal article

Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors

artículo científico publicado en 2017

Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.

artículo científico publicado en 2017

Selective Aurora Kinase Inhibitors Identified Using a Taxol-Induced Checkpoint Sensitivity Screen

artículo científico publicado en 2012

Small genomic insertions form enhancers that misregulate oncogenes

artículo científico publicado en 2017

Small molecules targeting the flavivirus E protein with broad-spectrum activity and antiviral efficacy in vivo

artículo científico publicado en 2019

Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function

artículo científico publicado en 2010

Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.

artículo científico publicado en 2017

THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors

artículo científico publicado en 2017

Targeting transcription regulation in cancer with a covalent CDK7 inhibitor

artículo científico publicado en 2014

Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor

artículo científico publicado en 2014

Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines

artículo científico publicado en 2014

Lista de obras de

Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors.

Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations

CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation

CDK13 cooperates with CDK12 to control global RNA polymerase II processivity

CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer

CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.

CDK7-dependent transcriptional addiction in triple-negative breast cancer.

Corrigendum: Small genomic insertions form enhancers that misregulate oncogenes

Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors

Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors

Cut homeobox 1 causes chromosomal instability by promoting bipolar division after cytokinesis failure

Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8

Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype

Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13

Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1.

Discovery of selective aminothiazole aurora kinase inhibitors

ER stress signaling promotes the survival of cancer 'persister cells' tolerant to EGFR tyrosine kinase inhibitors

EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma

Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs

High MITF Expression is Associated with Super-enhancers and Suppressed by CDK7 Inhibition in Melanoma.

High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors

Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML

Identification of small molecule inhibitors targeting the Zika virus envelope protein

Leveraging kinase inhibitors to develop small molecule tools for imaging kinases by fluorescence microscopy

MT FdR: a ferredoxin reductase from M. tuberculosis that couples to MT CYP51

Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors

Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.

Selective Aurora Kinase Inhibitors Identified Using a Taxol-Induced Checkpoint Sensitivity Screen

Small genomic insertions form enhancers that misregulate oncogenes

Small molecules targeting the flavivirus E protein with broad-spectrum activity and antiviral efficacy in vivo

Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function

Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.

THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors

Targeting transcription regulation in cancer with a covalent CDK7 inhibitor

Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor

Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines